AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 115 filers reported holding AKERO THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $61,792,271 | +10.1% | 1,221,674 | +1.7% | 3.15% | +3.9% |
| Q2 2023 | $56,102,284 | +13.7% | 1,201,591 | -6.8% | 3.03% | +55.5% |
| Q1 2023 | $49,339,752 | -49.9% | 1,289,591 | -28.2% | 1.95% | -55.2% |
| Q4 2022 | $98,388,194 | +32.9% | 1,795,405 | -17.5% | 4.36% | -4.7% |
| Q3 2022 | $74,057,000 | +316.2% | 2,174,946 | +15.5% | 4.57% | +349.6% |
| Q2 2022 | $17,792,000 | -19.3% | 1,882,698 | +21.2% | 1.02% | +1.1% |
| Q1 2022 | $22,037,000 | -32.8% | 1,552,990 | +0.1% | 1.01% | -39.9% |
| Q4 2021 | $32,806,000 | -3.5% | 1,551,090 | +2.0% | 1.67% | 0.0% |
| Q3 2021 | $33,999,000 | -8.6% | 1,521,190 | +1.5% | 1.67% | +11.8% |
| Q2 2021 | $37,189,000 | +377.8% | 1,498,938 | +458.7% | 1.50% | +324.1% |
| Q1 2021 | $7,783,000 | – | 268,282 | – | 0.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
| Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
| Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
| COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
| Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
| Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
| Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
| Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |